BWAY Stock Analysis: Buy, Sell, or Hold?
BWAY - Brainsway Ltd. American Depositary Shares
$16.47
-0.13 (-0.78%)
▼
5d:
+5.24%
30d:
+10.61%
90d:
+0.98%
WAIT
LOW Confidence
Analysis Updated: Aug 13, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When BWAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BWAY shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BWAY shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.53
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$14.61
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BWAY is currently trading at $16.47, which is considered extended relative to its 30-day fair value range of $14.79 to $16.17. From a valuation perspective, the stock is trading at a discount (Forward PE: 34.1) compared to its historical average (47.7). Remarkably, the market is currently pricing in an annual earnings decline of 10.6% over the next few years. This pessimistic expectation contrasts with the company's recent 200% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BWAY is in a uptrend. Immediate support is located at $14.81, while resistance sits at $17.40.
Market Sentiment: BWAY scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BWAY is in a uptrend. Immediate support is located at $14.81, while resistance sits at $17.40.
Market Sentiment: BWAY scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$14.79 -
$16.17
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
23.8%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($17.67)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$14.79 -
$16.17
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$14.81
Resistance Level
$17.40
Current Trend
Uptrend
Technical data as of
Aug 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
34.08
Wall Street Target
$17.67
(+7.3%)
Revenue Growth (YoY)
34.6%
Earnings Growth (YoY)
200.0%
Profit Margin
15.6%
Valuation Discount vs History
-10.6% cheaper
PE vs Historical
34.1 vs 47.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.6%
(market-implied from PE analysis)
1-Year Target
$14.82
(-10%)
2-Year Target
$13.34
(-19%)
3-Year Target
$12.01
(-27%)
3-Yr Target (if PE normalizes)
(PE: 34→48)
$16.81
(+2%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 34.1, Growth: 57.6%)
$55.59
(+238%)
Base:
(SPY PE: 20.2, Growth: 57.6%)
$33.00
(+100%)
Bear:
(PE: 17.2, Growth: 57.6%)
$28.05
(+70%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (37x PE), but valuation improves significantly next year (34x PE) as earnings recover.
Forward PE: 36.50 | Forward EPS (Implied): $0.45
Bull Case
$19.89
(+21%)
Analyst growth 15.0%, PE expands to 38.3
Base Case
$16.47
(0%)
Market implied 0.0%, PE stable at 36.5
Bear Case
$12.60
(-24%)
Severe decline -15.0%, PE contracts to 32.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 34.1 to 47.7
Stabilization Target:
$23.05
(+40.0%)
PE Expansion Potential:
+40.0%
Share & Embed Analysis
Last updated: August 13, 2026 10:33 PM ET
Data refreshes hourly during market hours. Next update: 11:33 PM
Data refreshes hourly during market hours. Next update: 11:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BWAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 33 SELL |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$382 | 50 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 52 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$93 | 30 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 34 SELL |
